Search

Herein the authors report a case of uterine adenosarcoma admixed with primitive neuroectodermal tumour (PNET) and review the literature on these rare neoplasms, as well as data files of their Gynaecologic Pathology Centre in Rome, Italy. [ABSTRACT FROM AUTHOR]

Objective: This study assessed the effectiveness and safety of a medical device containing purified bovine colostrum (Monurelle Biogel; Zambon, Bresso, Italy) in improving vulvovaginal atrophy (VVA), sexual function, urinary symptoms, and quality of life (QoL) in postmenopausal women. Methods: In all, 172 postmenopausal women with VVA were included in the study. All women were treated with vaginal Monurelle Biogel daily for 12 weeks. Patients underwent clinical examinations, completed a 3‐day voiding diary, and had VVA graded using the Vaginal Health Index (VHI) at baseline and 12 weeks. Patients also completed the Female Sexual Function Index (FSFI), overactive bladder questionnaire (OAB‐Q), and the Urogenital Distress Inventory (UDI‐6), among others. Results: After 12 weeks, there were significant increases in mean (± SD) VHI (12.53 ± 3.67 vs. 19.31 ± 3.49; P < .0001), the number of patients engaging in regular sexual activity 102 (59.3%) vs. 144 (83.7%), and in the total FSFI score (21.64 ± 2.99 vs. 28.16 ± 1.93; P < .0001) compared with baseline. In addition, there were significant reductions in the mean number of 24‐hour voids (9.57 ± 2.12 vs. 7.13 ± 1.22; P < .0001), urgent micturition episodes per 24 hours (1.75 ± 0.76 vs. 1.14 ± 0.87; P = .001), nocturia episodes (1.58 ± 0.85 vs. 0.97 ± 1.18; P = .0002), and urinary incontinence episodes per 24 hours (0.74 ± 0.59 vs. 0.28 ± 0.52; P = .003). Finally, after 12 weeks treatment, there were significant differences in UDI‐6 (7.85 ± 0.81 vs. 5.56 ± 1.40), OAB‐Q symptom (53.60 ± 12.57 vs. 22.08 ± 9.63), and OAB‐Q health‐related QoL (21.75 ± 8.51 vs. 69.34 ± 14.59) scores compared with baseline (P < .0001 for all). The Patient Impression of Global Improvement scale revealed global improvement in 143 women (83.14%). Conclusions: Monurelle Biogel is an effective treatment for VVA in postmenopausal women, improving sexual life, urinary symptoms, and QoL. [ABSTRACT FROM AUTHOR]

Background: Cutaneous relapse from endometrial cancer is a rare event, and often is part of a plurimetastatic disease with poor prognosis. Besides palliative chemotherapy, no consensus is present in literature about the specific treatment of skin metastases, in particular in order to improve symptoms. Objectives: In this paper the authors present a case of multi-metastatic endometrial cancer patient with also cutaneous metastasis, treated with palliative systemic therapy and electrochemotherapy. In particular the authors will describe the clinical, dermatoscopic, and pathological features of cutaneous metastases and their management. A literature review on cutaneous metastasis from endometrial cancer is also presented. Materials and Methods: A PubMed research was made using the terms "endometrial carcinoma", "skin", "cutaneous", "metastasis", and "spread". Discussion: The present case of unusual localization of skin metastases from endometrial cancer is the second described in the literature. The other known cases of cutaneous metastasis from endometrial cancer are summarized and reviewed. Electrochemotherapy can be proposed as an effective and safe loco-regional therapy for skin metastases, especially in case of multiple lesions. To the present authors' knowledge this is the first case of cutaneous metastases from endometrial cancer treated with electrochemotherapy. [ABSTRACT FROM AUTHOR]

OBJECTIVE: Urinary tract infections still represent a significant bother for women and result in high costs to the health system. D-mannose is a simple sugar; it seems able to hinder bacteria adhesion to the urothelium. The present study aimed to determine whether Dmannose alone is effective in treating acute urinary tract infections in women and its possible utility in the management of recurrences. PATIENTS AND METHODS: This is a pilot study, performed between April 2014 and July 2015 at Department of Gynaecological Obstetrics and Urologic Sciences of "Sapienza" University of Rome. A D-mannose compound was administered twice daily for 3 days and then once a day for 10 days. Changes in patients' symptoms, the therapeutic effects and changes in quality of life (QoL) were evaluated clinically and using a specifically validated questionnaire (UTISA). After described treatment, patients were randomized in receiving or not prophylaxis in the next 6 months. RESULTS: Mean UTISA scores recorded after completing the treatment, compared with baseline scores, showed a significant improvement of the majority of symptoms (p < 0.05). D-mannose seemed to have had a significant positive effect on UTIs' resolution and QoL improvement (p = 0.0001). As prophylactic agent administered for 6 months, it showed promising results (4.5% vs. 33.3% recurrences in treated and untreated patients respectively). CONCLUSIONS: The results of this study suggest that D-mannose can be an effective aid in acute cystitis management and also a successful prophylactic agent in a selected population; however, more studies will certainly be needed to confirm the results of our pilot study. [ABSTRACT FROM AUTHOR]